Advertisement

NLS Victoza

Pharma Business - August 11, 2017

Novo’s Victoza has been approved in the EU

The European Commission has approved an update to the Victoza (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment. Victoza is the only GLP-1 that is proven to prevent CV events in people with type 2 diabetes and high […]

Clinical Trials - June 11, 2016

Novo’s Victoza reduce risk of major cardiovascular events

Novo Nordisk has announced that Victoza (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), when added to standard of care in 9,340 adults with type 2 diabetes at high CV […]

Clinical Trials - June 8, 2015

Novo Drug Works During Ramadan Fast

Adults with type 2 diabetes treated with Novo Nordisk’s Victoza®, in combination with metformin, experienced similar improvements in blood glucose control while fasting during the four weeks of Ramadan compared with sulfonylurea (SU) plus metformin, according to a recent study.  People treated with Victoza® also demonstrated greater weight loss and fewer confirmed hypoglycemic episodes compared with […]

Pharma Business - January 22, 2015

EC Grants Extension to Victoza

The license extension for Novo Nordisk’s Victoza® means the drug is now available to almost one million people in the UK who are affected by type 2 diabetes and moderate renal impairment. The decision by the European Commission (EC) means clinicians can treat patients with one daily injection. providing an effective treatment in an area where few treatments are available […]

Drug Development Pharma - November 24, 2014

CHMP Approves Victoza

The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, a once-daily human glucagon-like peptide-1 (GLP-1) analogue, to […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.